Measuring EASIX 1 year post-alloSCT to predict late NRM risk

Kordelas L, Terzer T, Gooley TA, et al. EASIX-1 Year and Late Mortality After Allogeneic Stem Cell Transplantation. Blood Advances. 2023; (doi: 10.1182/bloodadvances.2022008617).

New research shows that calculating the Endothelial Activation and Stress Index (EASIX) 1 year after allogeneic stem cell transplantation (alloSCT) may predict late overall and non-relapse mortality (NRM) in disease-free patients. The retrospective study included two independent cohorts of relapse-free survivors at 1 year after alloSCT: a training cohort (N=610) and a merged validation cohort (N=852). There was a correlation between overall survival (OS), NRM, and relapse and EASIX measured at 1 year (EASIX-1y). In univariable and multivariable Cox regression analyses for both cohorts, EASIX-1y was an indicator of OS and NRM, but not risk of relapse. For overall survival, there was no meaningful interaction between the index and incidence of chronic graft-versus-host disease (GVHD). Pre-existing comorbidities did not affect EASIX-1y's ability to predict outcomes. Infections with and without GVHD and cardiovascular complications were the primary causes of NRM in both cohorts. There was a correlation between EASIX-1y and sCD141 and interleukin-18, but not with C-reactive protein, suppressor of tumorigenicity (ST)-2, angiopoietin-2, CXCL9, or CXCL8. Increased surveillance and prophylactic measures should be discussed for patients identified by EASIX-1y as high risk, the researchers suggest.

Read More

Tags: GVHD, transplantation, Cellular therapy, Research, Transplant, Graft versus host disease, Acute GVHD, cell therapy, graft-vs-host disease